Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
85/433 Publications
-
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
-
Non-invasive diagnosis and follow-up of portal hypertension.
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
-
The non-invasive assessment of hepatic fibrosis.
-
Noninvasive diagnosis in alcohol-related liver disease. Review
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
-
Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.
-
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
-
A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.
-
Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis.
-
The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
-
The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.
-
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
-
Liver fibrosis markers in alcoholic liver disease.
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
-
[Prognosis assessment of alcoholic liver disease: how and why?].
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
-
Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.
-
[The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].
-
Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
-
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Non-invasive markers for hepatic fibrosis.
-
Noninvasive assessment of portal hypertension in patients with cirrhosis.
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
-
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
-
Non-invasive assessment of liver fibrosis: are we ready?
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
-
Applicability and variability of liver stiffness measurements according to probe position.
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
-
Liver biopsy: the best standard...when everything else fails.
-
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
-
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
-
Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication
-
Assessment of liver fibrosis: noninvasive means.
-
Biomarkers of liver fibrosis.
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
-
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication
-
Reproducibility of blood tests of liver fibrosis in clinical practice.
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
-
FibroMAX: towards a new universal biomarker of liver disease?
-
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
-
Guidelines for the diagnosis of uncomplicated cirrhosis.
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
-
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
-
A novel panel of blood markers to assess the degree of liver fibrosis.
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
-
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
-
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
-
Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.
-
A simple biological index for detection of alcoholic liver disease in drinkers.
-
La Haute Autorite de Sante (HAS) in France— Diagnosis of uncomplicated cirrhosis (Accessed December 2011)
Showing the full result list. The page is server-rendered and not paginated.